Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670 | 1.00 | LMNA (0.59) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6918769 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| Methane SCHEMBL7758417 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6915202 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6914844 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL8714156 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6914848 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6915968 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL313548 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E | |
| SCHEMBL6917226 | 0.97 | LMNA (0.56) | LMNACA2TSHRALDH1A1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684469-A | Universal ABT compounds and uses thereof | 克莱奥药品有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-113993852-B | Process for preparing ClC-1 chloride channel inhibitors | NMD制药股份公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-111148527-B | Universal ABT compounds and uses thereof | 克莱奥药品有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-111093708-B | Bioorthogonal compositions | 坦伯公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-116964029-A | Method for producing D-erythro-sphingosine and analogues thereof | 碳码股份公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-109195955-B | Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compound- (S) -afoxolaner | 勃林格殷格翰动物保健美国公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114805234-A | Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compound- (S) -afoxolaner | 勃林格殷格翰动物保健美国公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20070203334-A1 | contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone | IDENIX PHARMACEUTICALS LLC | 2007-08-30 | — | — | US | disclosed |
| US-5414068-A | Bile seequestrants, free radical polymerization of amines | ROHM AND HAAS COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203334-A1 | contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone | RPN1, DAD1, RPN2 | LMNA 554/4885CA2 2689/4885TSHR 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.